CStone Pharmaceuticals
HKSE: 2616.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jianxin Yang
- Employees
- 135
- Headquarters
- Shanghai, China
- IPO year
- 2019
- Market cap
- HK$13.5B
- Website
- https://www.cstonepharma.com
Loading 2616…
Loading profile data…Frequently asked questions about 2616
What does CStone Pharmaceuticals (2616.HK) do?
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment...
Where does 2616.HK trade?
CStone Pharmaceuticals (2616.HK) trades on the Hong Kong Stock Exchange.
What sector is 2616.HK in?
CStone Pharmaceuticals (2616.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CStone Pharmaceuticals?
Jianxin Yang is the chief executive officer of CStone Pharmaceuticals (2616.HK).
Where is CStone Pharmaceuticals headquartered?
CStone Pharmaceuticals is headquartered in China.
Does 2616.HK pay a dividend?
CStone Pharmaceuticals (2616.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2616.HK go public?
CStone Pharmaceuticals (2616.HK) completed its initial public offering in 2019.